MicroStrategy could join the Nasdaq 100, replacing Moderna. Its Bitcoin investments fuel growth while tech classification circumvents rules.

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

Moderna Inc. closed $127.61 below its 52-week high ($170.47), which the company achieved on May 24th.

Fox News health commentator Dr. Kelly Powers was diagnosed with glioblastoma, an aggressive form of brain cancer, in July 2020, months before COVID-19 vaccines were made available in the U.S. But ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

Sanofi SNY announced that the FDA has granted a Fast Track designation to two combination vaccine candidates to prevent ...

MicroStrategy (MSTR) is expected to join the Nasdaq 100 stock index on Dec. 23, with an announcement coming as soon as this ...

A third dose of COVID-19 vaccine is beneficial among older Medicare beneficiaries, regardless of prior medically attended COVID-19 diagnoses.

A new mRNA therapy tested in mice may target the root cause of the potentially fatal pregnancy disorder preeclampsia. It's ...

When asked whether his fourth Senate term would be his last, Sanders (I-Vt.) said: “I’m 83 now. I’ll be 89 when I get out of ...

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...